Diaceutics (DXRX) investor relations material

Customer proposition and platform

• Claims data is retrospective; multimodal lab, genetics and EMR signals add patient-journey detail and help identify clinical intent before treatment decisions.

• Signal detects therapy-relevant diagnostic events in as little as 24 hours, links patient opportunities to treating HCPs and feeds commercial workflows.

• A network of 670+ lab and hospital partners supplies proprietary data; a two-way exchange of data, benchmarking and education supports partner retention and a data flywheel.

• Select partners grant exclusive access to the first 30 days of data; the approach is being expanded in stages and is intended to strengthen differentiation without materially affecting reuse economics.

• Customer proof points include identifying AML clinicians within 24 hours vs 38 days via claims, 7x reported ROI for Physician Engage and a 75% reduction in testing turnaround time.

Customer base and commercial model

• Works with 18 of the top 20 global pharma companies; 55 customers and 103 therapeutic brands form a differentiated distribution base, with some customer relationships extending beyond 20 years.

• Subscription products and services include Signal, Reveal, DXRX and Relay; the streamlined portfolio prioritizes high-margin recurring products, while Relay combines intelligence and engagement.

• H1 2026 Signal adoption reached 55 brands, up from 36 a year earlier; therapeutic brands served increased from 56 in 2022 to 103 in H1 2026.

• Four active Relay programs have estimated ARR of $11–12m; the first two programs grew from GBP 2.6m ARR at inception to GBP 4.3m.

Financial performance and visibility

• H1 2026 revenue grew 20% YoY, or 22% on a constant-currency basis; three-year revenue CAGR was ~21%.

• Recurring revenue increased 42% in H1 2026 and represented 75% of half-year revenue; TTM recurring revenue was 61%, up from 55% in the prior TTM period.

• ARR rose 79% to GBP 29.4m in the 12 months to June 2026 and 47% in H1 2026; NRR was 149%, gross ARR churn 6%, and customer ARR expansion GBP 13.3m.

• ARR of GBP 20m at 1 Jan 2026 covered ~43% of 2026 median analyst guidance; projected ARR of GBP 38.5m at 1 Jan 2027 would cover ~68% of 2027 guidance of GBP 56.3m.

• Gross margin was ~85%; profitability and free cash flow continued to improve as operating leverage increased.